Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HN3-SLANT conjugate
- Development stage
- Preclinical
- Lead developer
- National Cancer Institute
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
HN3-SLANT conjugate is a site-specifically labeled heterodimeric nanobody conjugate developed by the National Cancer Institute (NCI) and the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) for the molecular imaging of hepatocellular carcinoma (HCC). The conjugate utilizes Self-Labeling Nanobody-Tag (SLANT) technology, which consists of a target-specific single-domain antibody (HN3) targeting Glypican-3 (GPC3) genetically fused to a self-labeling nanobody (Nb6E). This heterodimeric construct is site-specifically labeled by covalent crosslinking with a peptide epitope functionalized with a chelator (such as DOTA) distal to the antigen-binding site. Labeled with radioisotopes like Indium-111 (111In) or Copper-64 (64Cu), the conjugate serves as a diagnostic PET/SPECT imaging tracer to detect GPC3-positive liver tumors.
- Other names
- 111In-HN3-Nb6E111In-HN3-SLANT conjugate64Cu-HN3-Nb6E64Cu-HN3-SLANT conjugateHN3-Nb6E conjugateHN-3-Nb6E conjugateHN 3-Nb6E conjugateHN3-SLANTHN-3-SLANTHN 3-SLANT
02
Targets
GPC3 (Glypican-3)
Beyond the preview
Go deeper on HN3-SLANT conjugate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HN3-SLANT conjugate.